Advances in hemorrhagic stroke therapy: conventional and novel approaches

• INGALL T: Stroke – incidence, mortality, morbidity and risk. J. Insur. Med. (2004) 36(2):143-152.
   PubMedGoogle Scholar
• FLAHERTY ML, WOO D, HAVERBUSCH M et al.: Racial variations in location and risk of intracerebral hemorrhage. Stroke (2005) 36(5):934-937.
   PubMed Web of Science ®Google Scholar
• STURGEON JD, FOLSOM AR: Trends in hospitalization rate, hospital case fatality, and mortality rate of stroke by subtype in Minneapolis-St. Paul, 1980 – 2002. Neuroepidemiology (2007) 28(1):39-45.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA: Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr. Neurol. Neurosci. Rep. (2002) 2(1):38-43.
   PubMedGoogle Scholar
• LYDEN PD, ZIVIN JA: Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc. Brain Metab. Rev. (1993) 5(1):1-16.
   PubMedGoogle Scholar
• BERNSTEIN RA, DEL-SIGNORE M: Recent advances in the management of acute intracerebral hemorrhage. Curr. Neurol. Neurosci. Rep. (2005) 5(6):483-487.
   PubMedGoogle Scholar
• VAN GIJN J, KERR RS, RINKEL GJ: Subarachnoid haemorrhage. Lancet (2007) 369(9558):306-318.
   PubMed Web of Science ®Google Scholar
• HORNIG CR, BAUER T, SIMON C, TRITTMACHER S, DORNDORF W: Hemorrhagic transformation in cardioembolic cerebral infarction. Stroke (1993) 24(3):465-468.
   PubMed Web of Science ®Google Scholar
• OKADA Y, YAMAGUCHI T, MINEMATSU K et al.: Hemorrhagic transformation in cerebral embolism. Stroke (1989) 20(5):598-603.
   PubMed Web of Science ®Google Scholar
• TONI D, FIORELLI M, BASTIANELLO S et al.: Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology (1996) 46(2):341-345.
   PubMed Web of Science ®Google Scholar
• KASNER SE: Clinical interpretation and use of stroke scales. Lancet Neurol. (2006) 5(7):603-612.
   PubMed Web of Science ®Google Scholar
• LYDEN P, CLAESSON L, HAVSTAD S, ASHWOOD T, LU M: Factor analysis of the National Institutes of Health Stroke Scale in patients with large strokes. Arch. Neurol. (2004) 61(11):1677-1680.
   PubMed Web of Science ®Google Scholar
• LYDEN P, RAMAN R, LIU L et al.: NIHSS training and certification using a new digital video disk is reliable. Stroke (2005) 36(11):2446-2449.
   PubMed Web of Science ®Google Scholar
• LYDEN PD, LU M, LEVINE SR, BROTT TG, BRODERICK J: A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity. Stroke (2001) 32(6):1310-1317.
   PubMed Web of Science ®Google Scholar
• CAVANAGH SJ, GORDON VL: Grading scales used in the management of aneurysmal subarachnoid hemorrhage: a critical review. J. Neurosci. Nurs. (2002) 34(6):288-295.
   PubMedGoogle Scholar
• GRASSO G: An overview of new pharmacological treatments for cerebrovascular dysfunction after experimental subarachnoid hemorrhage. Brain Res. Brain Res. Rev. (2004) 44(1):49-63.
   PubMed Web of Science ®Google Scholar
• CORDONNIER C, AL-SHAHI SALMAN R, WARDLAW J: Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain (2007).
   Google Scholar
• BERWAERTS J, ROBB OJ, DYKHUIZEN RS, WEBSTER J: Course, management and outcome of oral-anticoagulant-related intracranial haemorrhages. Scott. Med. J. (2000) 45(4):105-109.
   PubMed Web of Science ®Google Scholar
• FLAHERTY ML, KISSELA B, WOO D et al.: The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology (2007) 68(2):116-121.
   PubMed Web of Science ®Google Scholar
• KHATRI P, WECHSLER LR, BRODERICK JP: Intracranial hemorrhage associated with revascularization therapies. Stroke (2007) 38(2):431-440.
   PubMed Web of Science ®Google Scholar
• FAYAD PB, AWAD IA: Surgery for intracerebral hemorrhage. Neurology (1998) 51(3 Suppl. 3):S69-S73.
   PubMed Web of Science ®Google Scholar
• FEWEL ME, THOMPSON BG Jr, HOFF JT: Spontaneous intracerebral hemorrhage: a review. Neurosurg. Focus (2003) 15(4):E1.
   PubMedGoogle Scholar
• BRODERICK JP: The STICH trial: what does it tell us and where do we go from here? Stroke (2005) 36(7):1619-1620.
   PubMed Web of Science ®Google Scholar
• BRODERICK JP: Advances in the treatment of hemorrhagic stroke: a possible new treatment. Cleve. Clin. J. Med. (2005) 72(4):341-344.
   PubMed Web of Science ®Google Scholar
• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. (1995) 333(24):1581-1587.
   PubMed Web of Science ®Google Scholar
• ALBERS GW, BATES VE, CLARK WM, BELL R, VERRO P, HAMILTON SA: Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA (2000) 283(9):1145-1150.
   PubMed Web of Science ®Google Scholar
• ALBERTS MJ: t-PA in acute ischemic stroke: United States experience and issues for the future. Neurology (1998) 51(3 Suppl. 3):S53-S55.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA: Development of thrombolytic therapy for stroke: a perspective. Expert Opin. Investig. Drugs (2002) 11(11):1623-1632.
   PubMed Web of Science ®Google Scholar
• MENDELOW AD, UNTERBERG A: Surgical treatment of intracerebral haemorrhage. Curr. Opin. Crit. Care (2007) 13(2):169-174.
   PubMed Web of Science ®Google Scholar
• BHATTATHIRI PS, GREGSON B, PRASAD KS, MENDELOW AD: Intraventricular hemorrhage and hydrocephalus after spontaneous intracerebral hemorrhage: results from the STICH trial. Acta Neurochirurgica (2006) 96:65-68.
   Google Scholar
• BHATTATHIRI PS, GREGSON B, PRASAD KS et al.: Reliability assessment of computerized tomography scanning measurements in intracerebral hematoma. Neurosurg. Focus (2003) 15(4):E6.
   PubMedGoogle Scholar
• MAYER SA, RINCON F: Treatment of intracerebral haemorrhage. Lancet Neurol. (2005) 4(10):662-672.
   PubMed Web of Science ®Google Scholar
• PRASAD KS, GREGSON BA, BHATTATHIRI PS, MITCHELL P, MENDELOW AD: The significance of crossovers after randomization in the STICH trial. Acta Neurochirurgica (2006) 96:61-64.
   Google Scholar
• FINDLAY JM, JACKA MJ: Cohort study of intraventricular thrombolysis with recombinant tissue plasminogen activator for aneurysmal intraventricular hemorrhage. Neurosurgery (2004) 55(3):532-537; discussion 537-538.
   PubMed Web of Science ®Google Scholar
• MAYFRANK L, LIPPITZ B, GROTH M, BERTALANFFY H, GILSBACH JM: Effect of recombinant tissue plasminogen activator on clot lysis and ventricular dilatation in the treatment of severe intraventricular haemorrhage. Acta Neurochir. (Wien) (1993) 122(1-2):32-38.
   PubMed Web of Science ®Google Scholar
• NAFF NJ, TUHRIM S: Intraventricular hemorrhage in adults: complications and treatment. N. Horizons (Baltimore, Md) (1997) 5(4):359-363.
   PubMedGoogle Scholar
• RUSSO C, DE BIASE AM, BRUSCHI G, AGATI S, VITALI E: Successful intraventricular thrombolysis during ventricular assist device support. Ann. Thorac. Surg. (2002) 73(5):1628-1629.
   PubMed Web of Science ®Google Scholar
• SPUCK S, KONIG IR, ARNOLD H, ZIEGLER A, NOWAK G: Prospective studies in patients with intraventricular haemorrhage without the capacity to give consent in Germany – a legal dilemma. Zentralblatt fur Neurochirurgie (2006) 67(4):183-187.
   PubMedGoogle Scholar
• NAFF NJ, HANLEY DF, KEYL PM et al.: Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial. Neurosurgery (2004) 54(3):577-583; discussion 583-574.
   PubMed Web of Science ®Google Scholar
• BURKE RE, DORFMAN M, CHAN SB: Is emergent anti-hypertensive treatment beneficial in intracranial hemorrhage? J. Emerg. Med. (2005) 29(1):9-13.
   PubMed Web of Science ®Google Scholar
• QURESHI AI, HARRIS-LANE P, KIRMANI JF et al.: Treatment of acute hypertension in patients with intracerebral hemorrhage using American Heart Association guidelines. Crit. Care Med. (2006) 34(7):1975-1980.
   PubMed Web of Science ®Google Scholar
• STEINER T, DIRINGER MN, SCHNEIDER D et al.: Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery (2006) 59(4):767-773; discussion 773-764.
   PubMed Web of Science ®Google Scholar
• Interact. Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial: Progress Report. International Stroke Conference CT P33 (2007).
   Google Scholar
• YOU H, AL-SHAHI R: Haemostatic drug therapies for acute primary intracerebral haemorrhage. Cochrane Database Syst. Rev. (2006) 3:CD005951.
   PubMedGoogle Scholar
• LWALEED BA, GOYAL A, DELVES GH, COOPER AJ: Seminal hemostatic factors: then and now. Semin. Thromb. Hemost. (2007) 33(1):3-12.
   PubMed Web of Science ®Google Scholar
• HOOTS WK: Challenges in the therapeutic use of a “So-Called” universal hemostatic agent: recombinant factor VIIa. Hematol. Am. Soc. Hematol. Educ. Prog. (2006):426-431.
   Google Scholar
• MACIK BG: Treatment of factor VIII inhibitors: products and strategies. Semin. Thromb. Hemost. (1993) 19(1):13-24.
   PubMed Web of Science ®Google Scholar
• MACIK BG, LINDLEY CM, LUSHER J et al.: Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a Phase I study. Blood Coagul. Fibrinolysis (1993) 4(4):521-527.
   PubMed Web of Science ®Google Scholar
• MORRISSEY JH, MACIK BG, NEUENSCHWANDER PF, COMP PC: Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood (1993) 81(3):734-744.
   PubMed Web of Science ®Google Scholar
• HEMOPHILIA AND VON WILLEBRAND'S DISEASE: 2. Management. Association of Hemophilia Clinic Directors of Canada. CMAJ (1995) 153(2):147-157.
   PubMed Web of Science ®Google Scholar
• BLATT J, GOLD SH, WILEY JM, MONAHAN PE, COOPER HC, HARVEY D: Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant. (2001) 28(4):405-407.
   PubMed Web of Science ®Google Scholar
• DUNKLEY SM, MACKIE F: Recombinant factor VIIa used to control massive haemorrhage during renal transplantation surgery; vascular graft remained patent. Hematology (2003) 8(4):263-264.
   PubMedGoogle Scholar
• ROBERTS HR, MONROE DM, WHITE GC: The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood (2004) 104(13):3858-3864.
   PubMed Web of Science ®Google Scholar
• VELDMAN A, HOFFMAN M, EHRENFORTH S: New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr. Med. Chem. (2003) 10(10):797-811.
   PubMed Web of Science ®Google Scholar
• O'CONNELL KA, WOOD JJ, WISE RP, LOZIER JN, BRAUN MM: Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA (2006) 295(3):293-298.
   PubMed Web of Science ®Google Scholar
• MAYER SA, BRUN NC, BRODERICK J et al.: Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke (2005) 36(1):74-79.
   PubMed Web of Science ®Google Scholar
• MAYER SA, BRUN NC, BEGTRUP K et al.: Recombinant activated factor VII for acute intracerebral hemorrhage. N. Engl. J. Med. (2005) 352(8):777-785.
   PubMed Web of Science ®Google Scholar
• CADICHON SB, LE HOANG M, WRIGHT DA, CURRY DJ, KANG U, FRIM DM: Neuroprotective effect of the surfactant poloxamer 188 in a model of intracranial hemorrhage in rats. J. Neurosurg. (2007) 106(1 Suppl.):36-40.
   PubMedGoogle Scholar
• BELAYEV L, SAUL I, BUSTO R et al.: Albumin treatment reduces neurological deficit and protects blood–brain barrier integrity after acute intracortical hematoma in the rat. Stroke (2005) 36(2):326-331.
   PubMed Web of Science ®Google Scholar
• BELAYEV L, SAUL I, CURBELO K et al.: Experimental intracerebral hemorrhage in the mouse: histological, behavioral, and hemodynamic characterization of a double-injection model. Stroke (2003) 34(9):2221-2227.
   PubMed Web of Science ®Google Scholar
• MA B, ZHANG J: Nimodipine treatment to assess a modified mouse model of intracerebral hemorrhage. Brain Res. (2006) 1078(1):182-188.
   PubMed Web of Science ®Google Scholar
• ZHAO BQ, TEJIMA E, LO EH: Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke (2007) 38(2 Suppl.):748-752.
   PubMed Web of Science ®Google Scholar
• MCGIRT MJ, PRADILLA G, LEGNANI FG et al.: Systemic administration of simvastatin after the onset of experimental subarachnoid hemorrhage attenuates cerebral vasospasm. Neurosurgery (2006) 58(5):945-951; discussion 945-951.
   PubMed Web of Science ®Google Scholar
• PARRA A, MCGIRT MJ, SHENG H, LASKOWITZ DT, PEARLSTEIN RD, WARNER DS: Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: methodological analysis. Neurol. Res. (2002) 24(5):510-516.
   PubMed Web of Science ®Google Scholar
• PRUNELL GF, MATHIESEN T, DIEMER NH, SVENDGAARD NA: Experimental subarachnoid hemorrhage: subarachnoid blood volume, mortality rate, neuronal death, cerebral blood flow, and perfusion pressure in three different rat models. Neurosurgery (2003) 52(1):165-175; discussion 175-166.
   PubMed Web of Science ®Google Scholar
• PRUNELL GF, MATHIESEN T, SVENDGAARD NA: A new experimental model in rats for study of the pathophysiology of subarachnoid hemorrhage. Neuroreport (2002) 13(18):2553-2556.
   PubMed Web of Science ®Google Scholar
• JACKSON-FRIEDMAN C, LYDEN PD, NUNEZ S, JIN A, ZWEIFLER R: High dose baclofen is neuroprotective but also causes intracerebral hemorrhage: a quantal bioassay study using the intraluminal suture occlusion method. Exp. Neurol. (1997) 147(2):346-352.
   PubMed Web of Science ®Google Scholar
• LYDEN P, SHIN C, JACKSON-FRIEDMAN C, HASSID S, CHONG A, MACDONALD RL: Effect of ganaxolone in a rodent model of cerebral hematoma. Stroke (2000) 31(1):169-175.
   PubMed Web of Science ®Google Scholar
• LYDEN PD, JACKSON-FRIEDMAN C, LONZO-DOKTOR L: Medical therapy for intracerebral hematoma with the γ-aminobutyric acid-A agonist muscimol. Stroke (1997) 28(2):387-391.
   PubMed Web of Science ®Google Scholar
• ROMANIC AM, WHITE RF, ARLETH AJ, OHLSTEIN EH, BARONE FC: Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke (1998) 29(5):1020-1030.
   PubMed Web of Science ®Google Scholar
• ROSENBERG GA: Matrix metalloproteinases in brain injury. J. Neurotrauma (1995) 12(5):833-842.
   PubMed Web of Science ®Google Scholar
• ROSENBERG GA, NAVRATIL M: Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology (1997) 48(4):921-926.
   PubMed Web of Science ®Google Scholar
• WANG J, TSIRKA SE: Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain (2005) 128(Part 7):1622-1633.
   PubMed Web of Science ®Google Scholar
• KITAOKA T, HUA Y, XI G, HOFF JT, KEEP RF: Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage. Stroke (2002) 33(12):3012-3018.
   PubMed Web of Science ®Google Scholar
• KITAOKA T, HUA Y, XI G, NAGAO S, HOFF JT, KEEP RF: Effect of delayed argatroban treatment on intracerebral hemorrhage-induced edema in the rat. Acta Neurochirurgica (2003) 86:457-461.
   Google Scholar
• LAPCHAK PA, ARAUJO DM: Spin trap agents: a new approach to stroke therapy. Drug News Perspect. (2002) 15(4):220-225.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM: Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs (2001) 15(11):819-829.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM, SONG D, WEI J, PURDY R, ZIVIN JA: Effects of the spin trap agent disodium-[tert- butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator. Stroke (2002) 33(6):1665-1670.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM, SONG D, ZIVIN JA: The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke. Stroke (2002) 33(1):147-152.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, CHAPMAN DF, ZIVIN JA: Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke (2000) 31(12):3034-3040.
   PubMed Web of Science ®Google Scholar
• BROTT T, ADAMS HP Jr, OLINGER CP et al.: Measurements of acute cerebral infarction: a clinical examination scale. Stroke (1989) 20(7):864-870.
   PubMed Web of Science ®Google Scholar
• LYDEN PD, MADDEN KP, CLARK WM, SASSE KC, ZIVIN JA: Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. Stroke (1990) 21(11):1589-1593.
   PubMed Web of Science ®Google Scholar
• LYDEN PD, ZIVIN JA, CLARK WA et al.: Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology (1989) 39(5):703-708.
   PubMed Web of Science ®Google Scholar
• LYDEN PD, ZIVIN JA, SOLL M, SITZER M, ROTHROCK JF, ALKSNE J: Intracerebral hemorrhage after experimental embolic infarction. Anticoagulation. Arch. Neurol. (1987) 44(8):848-850.
   PubMed Web of Science ®Google Scholar
• BOWES MP, ZIVIN JA, THOMAS GR, THIBODEAUX H, FAGAN SC: Acute hypertension, but not thrombolysis, increases the incidence and severity of hemorrhagic transformation following experimental stroke in rabbits. Exp. Neurol. (1996) 141(1):40-46.
   PubMed Web of Science ®Google Scholar
• FEUERSTEIN GZ, WANG X, BARONE FC: Inflammatory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets. Ann. NY Acad Sci. (1997) 825:179-193.
   PubMed Web of Science ®Google Scholar
• JEAN WC, SPELLMAN SR, NUSSBAUM ES, LOW WC: Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery (1998) 43(6)1382-1396; discussion 1396-1387.
   Google Scholar
• LOVE S: Oxidative stress in brain ischemia. Brain Pathol. (1999) 9(1):119-131.
   PubMed Web of Science ®Google Scholar
• MUN-BRYCE S, ROSENBERG GA: Matrix metalloproteinases in cerebrovascular disease. J. Cereb. Blood Flow Metab. (1998) 18(11):1163-1172.
   PubMed Web of Science ®Google Scholar
• ROTHMAN SM, OLNEY JW: Glutamate and the pathophysiology of hypoxic–ischemic brain damage. Ann. Neurol. (1986) 19(2):105-111.
   PubMed Web of Science ®Google Scholar
• SIESJO BK, KATSURA K, ZHAO Q et al.: Mechanisms of secondary brain damage in global and focal ischemia: a speculative synthesis. J. Neurotrauma (1995) 12(5):943-956.
   PubMed Web of Science ®Google Scholar
• SIESJO BK, SIESJO P: Mechanisms of secondary brain injury. Eur. J. Anaesthesiol. (1996) 13(3):247-268.
   PubMed Web of Science ®Google Scholar
• RIKKERT MG, DEKKERS WJ, SCHELTENS P, VERHEY F: Memantine in moderate-to-severe Alzheimer disease evidence and ethics based? Alzheimer Dis. Assoc. Disord. (2004) 18(1):47-48; author reply 48.
   PubMed Web of Science ®Google Scholar
• HIRSCH CH: Memantine was better than placebo in Alzheimer disease already being treated with donepezil. ACP J. Club (2004) 141(2):38.
   PubMedGoogle Scholar
• FINUCANE TE: Memantine for patients with Alzheimer disease. JAMA (2004) 291(14):1695; author reply 1695.
   PubMedGoogle Scholar
• KORNHUBER J, BORMANN J, RETZ W, HUBERS M, RIEDERER P: Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. (1989) 166(3):589-590.
   PubMed Web of Science ®Google Scholar
• PARSONS CG, DANYSZ W, QUACK G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist – a review of preclinical data. Neuropharmacology 38(6):735-767.
   PubMed Web of Science ®Google Scholar
• PARSONS CG, GRUNER R, ROZENTAL J, MILLAR J, LODGE D: Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology (1993) 32(12):1337-1350.
   PubMed Web of Science ®Google Scholar
• FRANKIEWICZ T, POTIER B, BASHIR ZI, COLLINGRIDGE GL, PARSONS CG: Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br. J. Pharmacol. (1996) 117(4):689-697.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA: Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits. Brain Res. (2006) 1088(1):141-147.
   PubMed Web of Science ®Google Scholar
• CHEN HS, WANG YF, RAYUDU PV et al.: Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience (1998) 86(4):1121-1132.
   PubMed Web of Science ®Google Scholar
• STIEG PE, SATHI S, WARACH S, LE DA, LIPTON SA: Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. Eur. J. Pharmacol. (1999) 375(1-3):115-120.
   PubMed Web of Science ®Google Scholar
• DOGAN A, ERAS MA, RAO VL, DEMPSEY RJ: Protective effects of memantine against ischemia-reperfusion injury in spontaneously hypertensive rats. Acta Neurochir. (Wien) (1999) 141(10):1107-1113.
   PubMed Web of Science ®Google Scholar
• LAGREZE WA, KNORLE R, BACH M, FEUERSTEIN TJ: Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest. Ophthalmol. Vis. Sci. (1998) 39(6):1063-1066.
   PubMed Web of Science ®Google Scholar
• RAO VL, DOGAN A, TODD KG, BOWEN KK, DEMPSEY RJ: Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Res. (2001) 911(1):96-100.
   PubMed Web of Science ®Google Scholar
• SOBRADO M, RODA JM, LOPEZ MG, EGEA J, GARCIA AG: Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. Neurosci. Lett. (2004) 365(2):132-136.
   PubMed Web of Science ®Google Scholar
• LEE ST, CHU K, JUNG KH et al.: Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. J. Cereb. Blood Flow Metab. (2006) 26(4):536-544.
   PubMed Web of Science ®Google Scholar
• SINN DI, LEE ST, CHU K et al.: Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. Neurosci. Lett. (2007) 411(3):238-242.
   PubMed Web of Science ®Google Scholar
• MCGEEHAN GM, BECHERER JD, BAST RC Jr et al.: Regulation of TNF-α processing by a metalloproteinase inhibitor. Nature (1994) 370(6490):558-561.
   PubMed Web of Science ®Google Scholar
• ZASK A, LEVIN JI, KILLAR LM, SKOTNICKI JS: Inhibition of matrix metalloproteinases: structure based design. Curr. Pharm. Des. (1996) 2:624-661.
   Web of Science ®Google Scholar
• YAMAMOTO M, HIRAYAMA R, NARUSE K et al.: Structure–activity relationship of hydroxamate-based inhibitors on membrane-bound Fas ligand and TNF-α processing. Drug Des. Discov. (1999) 16(2):119-130.
   PubMedGoogle Scholar
• BLACK RA, DURIE FH, OTTEN-EVANS C et al.: Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-α (TNF-α) production suggest the major TNF-α converting enzyme is not an MMP. Biochem. Biophys. Res. Commun. (1996) 225(2):400-405.
   PubMed Web of Science ®Google Scholar
• CHERNEY RJ, WANG L, MEYER DT et al.: Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-α production. Bioorg. Med. Chem. Lett. (1999) 9(9):1279-1284.
   PubMed Web of Science ®Google Scholar
• DAYER JM, BEUTLER B, CERAMI A: Cachectin/TNF stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J. Exp. Med. (1985) 162(6):2163-2168.
   PubMed Web of Science ®Google Scholar
• ROSENBERG GA, CUNNINGHAM LA, WALLACE J et al.: Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res. (2001) 893(1-2):104-112.
   PubMed Web of Science ®Google Scholar
• GEARING AJ, BECKETT P, CHRISTODOULOU M et al.: Processing of TNF-α precursor by metalloproteinases. Nature (1994) 370(6490):555-557.
   PubMed Web of Science ®Google Scholar
• CORBEL M, LANCHOU J, GERMAIN N, MALLEDANT Y, BOICHOT E, LAGENTE V: Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice. Eur. J. Pharmacol. (2001) 426(1-2):113-121.
   PubMed Web of Science ®Google Scholar
• FALK V, SOCCAL PM, GRUNENFELDER J, HOYT G, WALTHER T, ROBBINS RC: Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury. Eur. J. Cardiothorac. Surg. (2002) 22(1):53-58.
   PubMed Web of Science ®Google Scholar
• SANTUCCI MB, CIARAMELLA A, MATTEI M, SUMERSKA T, FRAZIANO M: Batimastat reduces Mycobacterium tuberculosis-induced apoptosis in macrophages. Int. Immunopharmacol. (2003) 3(12):1657-1665.
   PubMed Web of Science ®Google Scholar
• BECK G, BOTTOMLEY G, BRADSHAW D et al.: (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′-isobutyl-2′(meth anesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of TNF-α convertase. J. Pharmacol. Exp. Ther. (2002) 302(1):390-396.
   PubMed Web of Science ®Google Scholar
• WANG X, FEUERSTEIN GZ, XU L et al.: Inhibition of TNF-α-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol. Pharmacol. (2004) 65(4):890-896.
   PubMed Web of Science ®Google Scholar
• HEO JH, LUCERO J, ABUMIYA T, KOZIOL JA, COPELAND BR, DEL ZOPPO GJ: Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J. Cereb. Blood Flow Metab. (1999) 19(6):624-633.
   PubMed Web of Science ®Google Scholar
• ASAHI M, ASAHI K, JUNG JC, DEL ZOPPO GJ, FINI ME, LO EH: Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab. (2000) 20(12):1681-1689.
   PubMed Web of Science ®Google Scholar
• LEE SR, TSUJI K, LO EH: Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J. Neurosci. (2004) 24(3):671-678.
   PubMed Web of Science ®Google Scholar
• SUMII T, LO EH: Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke (2002) 33(3):831-836.
   PubMed Web of Science ®Google Scholar
• LO EH, WANG X, CUZNER ML: Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J. Neurosci. Res. (2002) 69(1):1-9.
   PubMed Web of Science ®Google Scholar
• DITTMAR M, KIOURKENIDIS G, HORN M, BOLLWEIN S, BERNHARDT G: Cerebral ischemia, matrix metalloproteinases, and TNF-α: MMP inhibitors may act not exclusively by reducing MMP activity. Stroke (2004) 35(7):E338-E340;
   PubMed Web of Science ®Google Scholar
• PFEFFERKORN T, ROSENBERG GA: Closure of the blood–brain barrier by matrix metalloproteinase inhibition reduces rt-PA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke (2003) 34(8):2025-2030.
   PubMed Web of Science ®Google Scholar
• ARAUJO DM, LAPCHAK PA: Tumor necrosis factor is involved in behavioral deficits, infarct progression and hemorrhage following ischemic strokes: a potential therapeutic target. In: SFN. (Eds).
   Google Scholar
• LAPCHAK PA: Tumor Necrosis Factor-α is involved in thrombolytic-induced hemorrhage following embolic strokes in rabbits. Brain Research (in press). (2007).
   Google Scholar
• HORSTMANN S, KALB P, KOZIOL J, GARDNER H, WAGNER S: Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke (2003) 34(9):2165-2170.
   PubMed Web of Science ®Google Scholar
• HORSTMANN S, SU Y, KOZIOL J, MEYDING-LAMADE U, NAGEL S, WAGNER S: MMP-2 and MMP-9 levels in peripheral blood after subarachnoid hemorrhage. J. Neurol. Sci. (2006) 251(1-2):82-86.
   PubMed Web of Science ®Google Scholar
• TODOR DR, LEWIS I, BRUNO G, CHYATTE D: Identification of a serum gelatinase associated with the occurrence of cerebral aneurysms as pro-matrix metalloproteinase-2. Stroke (1998) 29(8):1580-1583.
   PubMed Web of Science ®Google Scholar
• FUJIMURA M, WATANABE M, SHIMIZU H, TOMINAGA T: Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) in cerebral cavernous malformations: immunohistochemical analysis of MMP-2, -9 and TIMP-2. Acta Neurochir. (Wien.) (2007) 149(2):179-183.
   PubMed Web of Science ®Google Scholar
• FACCHINETTI F, DAWSON VL, DAWSON TM: Free radicals as mediators of neuronal injury. Cell. Mol. Neurobiol. (1998) 18(6):667-682.
   PubMed Web of Science ®Google Scholar
• FLOYD RA: Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. (1999) 222(3):236-245.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA M, NIWA M, IWAI T, UEMATSU T: Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat. Free Radic. Biol. Med. (1999) 26(5-6):722-729.
   PubMed Web of Science ®Google Scholar
• CHERUBINI A, RUGGIERO C, POLIDORI MC, MECOCCI P: Potential markers of oxidative stress in stroke. Free Radic. Biol. Med. (2005) 39(7):841-852.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM: Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke. CNS Drug Rev. (2003) 9(3):253-262.
   PubMedGoogle Scholar
• Becker DA: Diagnostic and therapeutic applications of azulenyl nitrone spin traps. Cell Mol. Life Sci. (1999) 56(7-8):626-633.
   PubMed Web of Science ®Google Scholar
• THOMAS CE, OHLWEILER DF, CARR AA et al.: Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps. J. Biol. Chem. (1996) 271(6):3097-3104.
   PubMed Web of Science ®Google Scholar
• MILATOVIC D, RADIC Z, ZIVIN M, DETTBARN WD: Atypical effect of some spin trapping agents: reversible inhibition of acetylcholinesterase. Free Radic. Biol. Med. (2000) 28(4):597-603.
   PubMed Web of Science ®Google Scholar
• ANDERSON KM, ELLS G, BONOMI P, HARRIS JE: Free radical spin traps as adjuncts for the prevention and treatment of disease. Med. Hypotheses (1999) 52(1):53-57.
   PubMed Web of Science ®Google Scholar
• CHEN GM, BRAY TM, JANZEN EG, MCCAY PB: Excretion, metabolism and tissue distribution of a spin trapping agent, α-phenyl-N-tert-butyl-nitrone (PBN) in rats. Free Radic. Res. Commun. (1990) 9(3-6):317-323.
   PubMed Web of Science ®Google Scholar
• YUE TL, GU JL, LYSKO PG, CHENG HY, BARONE FC, FEUERSTEIN G: Neuroprotective effects of phenyl-t-butyl-nitrone in gerbil global brain ischemia and in cultured rat cerebellar neurons. Brain Res. (1992) 574(1-2):193-197.
   PubMed Web of Science ®Google Scholar
• FOLBERGROVA J, ZHAO Q, KATSURA K, SIESJO BK: N-tert-butyl-α-phenylnitrone improves recovery of brain energy state in rats following transient focal ischemia. Proc. Natl. Acad. Sci. USA (1995) 92(11):5057-5061.
   PubMed Web of Science ®Google Scholar
• BECKER DA, LEY JJ, ECHEGOYEN L, ALVARADO R: Stilbazulenyl nitrone (STAZN): a nitronyl-substituted hydrocarbon with the potency of classical phenolic chain-breaking antioxidants. J. Am. Chem. Soc. (2002) 124(17):4678-4684.
   PubMed Web of Science ®Google Scholar
• MAPLES KR, MA F, ZHANG YK: Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059. Free Radic. Res. (2001) 34(4):417-426.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM, SONG D, WEI J, ZIVIN JA: Neuroprotective effects of the spin trap agent disodium-[(tertbutylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke (2002) 33(5):1411-1415.
   PubMed Web of Science ®Google Scholar
• PEELING J, DEL BIGIO MR, CORBETT D, GREEN AR, JACKSON DM: Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Neuropharmacology (2001) 40(3):433-439.
   PubMed Web of Science ®Google Scholar
• NILSSON D, WEMER J, CHENG YF et al.: NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover Phase I study. J. Clin. Pharmacol. (2007) 47(2):264-272.
   PubMed Web of Science ®Google Scholar
• Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc. Dis. (2003) 15(3):222-229.
   PubMed Web of Science ®Google Scholar
• YOSHIDA H, YANAI H, NAMIKI Y, FUKATSU-SASAKI K, FURUTANI N, TADA N: Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev. (2006) 12(1):9-20.
   PubMedGoogle Scholar
• ARAKI Y, ANDOH A, YOKONO T et al.: The free radical scavenger edaravone suppresses experimental closed duodenal loop-induced acute pancreatitis in rats. Int. J. Mol. Med. 12(1):121-124.
   PubMed Web of Science ®Google Scholar
• NITO C, KAMIYA T, AMEMIYA S, KATOH K, KATAYAMA Y: The neuroprotective effect of a free radical scavenger and mild hypothermia following transient focal ischemia in rats. Acta Neurochirurgica (2003) 86:199-203.
   Google Scholar
• WU TW, ZENG LH, WU J, FUNG KP: MCI-186: further histochemical and biochemical evidence of neuroprotection. Life Sci. (2000) 67(19):2387-2392.
   PubMed Web of Science ®Google Scholar
• YOSHIDA H, SASAKI K, NAMIKI Y, SATO N, TADA N: Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase. Atherosclerosis (2005) 179(1):97-102.
   PubMed Web of Science ®Google Scholar
• YOSHIFUMI T: Benefits of pre-treatmetn with edaravone in t-PA intravenous therapy for acute cerebral infarction. In: XXIIIrd International Symposium on Cerebral Blood Flow (Abstract) (2007). (Eds).
   Google Scholar
• SCHAFER AI: Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood (2006) 107(11):4214-4222.
   PubMed Web of Science ®Google Scholar
• SHARPLES EJ, YAQOOB MM: Erythropoietin in experimental acute renal failure. Nephron. Exp. Nephrol. (2006) 104(3):E83-E88.
   PubMed Web of Science ®Google Scholar
• HARDEE ME, ARCASOY MO, BLACKWELL KL, KIRKPATRICK JP, DEWHIRST MW: Erythropoietin biology in cancer. Clin. Cancer Res. (2006) 12(2):332-339.
   PubMed Web of Science ®Google Scholar
• CORWIN HL: The role of erythropoietin therapy in the critically ill. Transfus. Med. Rev. (2006) 20(1):27-33.
   PubMed Web of Science ®Google Scholar
• CERSOSIMO RJ, JACOBSON DR: Epoetin α versus darbepoetin α in chemotherapy-related anemia. Ann. Pharmacother. (2006) 40(1):58-65; quiz 169-170.
   PubMed Web of Science ®Google Scholar
• HEUSER M, GANSER A: Recombinant human erythropoietin in the treatment of nonrenal anemia. Ann. Hematol. (2006) 85(2):69-78.
   PubMedGoogle Scholar
• WOJCHOWSKI DM, HE TC: Signal transduction in the erythropoietin receptor system. Stem Cells (1993) 11(5):381-392.
   PubMed Web of Science ®Google Scholar
• RICHMOND TD, CHOHAN M, BARBER DL: Turning cells red: signal transduction mediated by erythropoietin. Trends Cell. Biol. (2005) 15(3):146-155.
   PubMed Web of Science ®Google Scholar
• SHARPLES EJ, THIEMERMANN C, YAQOOB MM: Novel applications of recombinant erythropoietin. Curr. Opin. Pharmacol. (2006) 6(2):184-189.
   PubMed Web of Science ®Google Scholar
• BARTESAGHI S, MARINOVICH M, CORSINI E, GALLI CL, VIVIANI B: Erythropoietin: a novel neuroprotective cytokine. Neurotoxicology (2005) 26(5):923-928.
   PubMed Web of Science ®Google Scholar
• EHRENREICH H, AUST C, KRAMPE H et al.: Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab. Brain Dis. (2004) 19(3-4):195-206.
   PubMed Web of Science ®Google Scholar
• FU ES, TUMMALA RP: Neuroprotection in brain and spinal cord trauma. Curr. Opin. Anaesthesiol. (2005) 18(2):181-187.
   PubMed Web of Science ®Google Scholar
• GENC S, KOROGLU TF, GENC K: Erythropoietin as a novel neuroprotectant. Restor. Neurol. Neurosci. (2004) 22(2):105-119.
   PubMed Web of Science ®Google Scholar
• GENC S, KOROGLU TF, GENC K: Erythropoietin and the nervous system. Brain Res. (2004) 1000(1-2):19-31.
   PubMed Web of Science ®Google Scholar
• HOKE A, KESWANI SC: Neuroprotection in the PNS: erythropoietin and immunophilin ligands. Ann. NY Acad. Sci. (2005) 1053:491-501.
   PubMed Web of Science ®Google Scholar
• KWON BK, FISHER CG, DVORAK MF, TETZLAFF W: Strategies to promote neural repair and regeneration after spinal cord injury. Spine (2005) 30(17 Suppl.):S3-S13.
   Google Scholar
• MILANO M, COLLOMP R: Erythropoietin and neuroprotection: a therapeutic perspective. J. Oncol Pharm. Pract. (2005) 11(4):145-149.
   PubMedGoogle Scholar
• WANG KK, LARNER SF, ROBINSON G, HAYES RL: Neuroprotection targets after traumatic brain injury. Curr. Opin. Neurol. (2006) 19(6):514-519.
   PubMed Web of Science ®Google Scholar
• FORTUNAT S, ROGGLA G: Is erythropoietin therapy in cancer patients safe? Wien. Med. Wochenschr. (2004) 154(23-24):590; author reply 591.
   PubMedGoogle Scholar
• KHORANA AA, FRANCIS CW, CULAKOVA E, LYMAN GH: Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 104(12):2822-2829.
   PubMed Web of Science ®Google Scholar
• SINGBARTL G: Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin. Investig. (1994) 72(6 Suppl.):S36-S43.
   PubMedGoogle Scholar
• STEURER M, SUDMEIER I, STAUDER R, GASTL G: Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-α. Br. J. Haematol. (2003) 121(1):101-103.
   PubMed Web of Science ®Google Scholar
• FANTACCI M, BIANCIARDI P, CARETTI A et al.: Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc. Natl. Acad. Sci. USA (2006) 103(46):17531-17536.
   PubMed Web of Science ®Google Scholar
• VILLA P, VAN BEEK J, LARSEN AK et al.: Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J. Cereb. Blood Flow Metab. (2007) 27(3):552-563.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, SALGADO KF, KIRKEBY A, SAGER TN: Nonerythropoietic carbamylerythropoietin improves clinical rating scores in embolized rabbits following multiple infarct ischemic strokes: a Therapeutic Window Study. Stroke submitted (2007).
   Google Scholar
• LEE ST, CHU K, SINN DI et al.: Erythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhage. J. Neurochem. (2006) 96(6):1728-1739.
   PubMed Web of Science ®Google Scholar
• PARK HK, CHU K, LEE ST: Granulocyte colony-stimulating factor induces sensorimotor recovery in intracerebral hemorrhage. Brain Res. (2005) 1041(2):125-131.
   PubMed Web of Science ®Google Scholar
• BAYS H: Statin safety: an overview and assessment of the data–2005. Am. J. Cardiol. (2006) 97(8A):C6-C26.
   PubMed Web of Science ®Google Scholar
• ENDRES M: Statins and stroke. J. Cereb. Blood Flow Metab. (2005) 25(9):1093-1110.
   PubMed Web of Science ®Google Scholar
• HALCOX JP, DEANFIELD JE: Beyond the laboratory: clinical implications for statin pleiotropy. Circulation (2004) 109(21 Suppl. 1):II42-II48.
   PubMed Web of Science ®Google Scholar
• LIAO JK: Statins and ischemic stroke. Atheroscler. Suppl. (2002) 3(1):21-25.
   PubMed Web of Science ®Google Scholar
• MOONIS M, FISHER M: HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke. Expert Rev. Neurother. (2004) 4(2):241-247.
   PubMed Web of Science ®Google Scholar
• RUTISHAUSER J: The role of statins in clinical medicine–LDL–cholesterol lowering and beyond. Swiss. Med. Wkly (2006) 136(3-4):41-49.
   PubMed Web of Science ®Google Scholar
• SCHMEER C, KRETZ A, ISENMANN S: Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins. Restor. Neurol. Neurosci. (2006) 24(2):79-95.
   PubMed Web of Science ®Google Scholar
• VIVANCOS-MORA J, GIL-NUNEZ AC: Lipids and stroke: the opportunity of lipid-lowering treatment. Cerebrovasc. Dis. (2005) 20(Suppl. 2):53-67.
   PubMed Web of Science ®Google Scholar
• WALDMAN A, KRITHARIDES L: The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. Drugs (2003) 63(2):139-152.
   PubMed Web of Science ®Google Scholar
• WERNER N, NICKENIG G, LAUFS U: Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res. Cardiol. (2002) 97(2):105-116.
   PubMed Web of Science ®Google Scholar
• DELANTY N, VAUGHAN CJ: Vascular effects of statins in stroke. Stroke (1997) 28(11):2315-2320.
   PubMed Web of Science ®Google Scholar
• HEBERT PR, GAZIANO JM, CHAN KS, HENNEKENS CH: Cholesterol lowering with statin drugs, risk of Stroke and total mortality. An overview of randomized trials. JAMA (1997) 278(4):313-321.
   PubMed Web of Science ®Google Scholar
• KASHYAP ML: Cholesterol and atherosclerosis: a contemporary perspective. Ann. Acad. Med. Singapore (1997) 26(4):517-523.
   PubMedGoogle Scholar
• ENDRES M: Statins: potential new indications in inflammatory conditions. Atheroscler. Suppl. (2006) 7(1):31-35.
   PubMed Web of Science ®Google Scholar
• ZIVIN JA: Clinical trials of neuroprotective therapies. Stroke (2007) 38(2 Suppl.):791-793.
   PubMed Web of Science ®Google Scholar
• SEYFRIED D, HAN Y, LU D, CHEN J, BYDON A, CHOPP M: Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J. Neurosurg. (2004) 101(1):104-107.
   PubMed Web of Science ®Google Scholar
• JUNG KH, CHU K, JEONG SW et al.: HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke (2004) 35(7):1744-1749.
   PubMed Web of Science ®Google Scholar
• Function of the src gene product. Science (1978) 201(4357):702.
   PubMed Web of Science ®Google Scholar
• COLLETT MS, ERIKSON E, ERIKSON RL: Structural analysis of the avian sarcoma virus transforming protein: sites of phosphorylation. J. Virol. (1979) 29(2):770-781.
   PubMed Web of Science ®Google Scholar
• COLLETT MS, ERIKSON RL: Protein kinase activity associated with the avian sarcoma virus src gene product. Proc. Natl. Acad. Sci. USA (1978) 75(4):2021-2024.
   PubMed Web of Science ®Google Scholar
• EISENMAN RN, VOGT VM: The biosynthesis of oncovirus proteins. Biochim. Biophys. Acta (1978) 473(3-4):187-239.
   PubMed Web of Science ®Google Scholar
• CHOU MT, WANG J, FUJITA DJ: Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. BMC Biochem. (2002) 3:32.
   PubMedGoogle Scholar
• KUSAKA G, ISHIKAWA M, NANDA A, GRANGER DN, ZHANG JH: Signaling pathways for early brain injury after subarachnoid hemorrhage. J. Cereb. Blood. Flow Metab. (2004) 24(8):916-925.
   PubMed Web of Science ®Google Scholar
• ARDIZZONE TD, ZHAN X, ANDER BP, SHARP FR: Src kinase inhibition improves acute outcomes after experimental intracerebral hemorrhage. Stroke (2007).
   Google Scholar
• ZHANG L, ZHANG ZG, LIU X et al.: Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thromb. Haemost. (2006) 95(1):166-173.
   PubMed Web of Science ®Google Scholar
• ZHANG ZG, ZHANG L, TSANG W et al.: Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Brain Res. (2001) 912(2):181-194.
   PubMed Web of Science ®Google Scholar
• SINN DI, LEE ST, CHU K et al.: Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib. Neurosci. Res. (2007) 58(1):12-18.
   PubMed Web of Science ®Google Scholar
• WATANABE M, OKADA T: Lysophosphatidylcholine-induced myocardial damage is inhibited by pretreatment with poloxamer 188 in isolated rat heart. Mol. Cell Biochem. (2003) 248(1-2):209-215.
   PubMed Web of Science ®Google Scholar
• SEYFRIED D, DING J, HAN Y, LI Y, CHEN J, CHOPP M: Effects of intravenous administration of human bone marrow stromal cells after intracerebral hemorrhage in rats. J. Neurosurg. (2006) 104(2):313-318.
   PubMed Web of Science ®Google Scholar
• LEE HJ, KIM KS, PARK IH, KIM SU: Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS One (2007) 2:E156.
   PubMed Web of Science ®Google Scholar
• LEE HJ, KIM KS, KIM EJ et al.: Brain transplantation of immortalized human neural stem cells promotes functional recovery in mouse intracerebral hemorrhage stroke model. Stem Cells (2007).
   Google Scholar
• LU A, TANG Y, RAN R, ARDIZZONE TL, WAGNER KR, SHARP FR: Brain genomics of intracerebral hemorrhage. J. Cereb. Blood Flow Metab. (2006) 26(2):230-252.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM: Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin. Emerging Drugs (2007) 12(1):97-112.
   PubMed Web of Science ®Google Scholar

Websites

• http://www.strokecenter.org/trials/scales/scales-overview.htm
   Google Scholar
• http://www.novonordisk.com
   Google Scholar
• http://news.bbc.co.uk/go/pr/fr/-/2/hu/uk_news/england/2807523.stm
   Google Scholar
• http://www.rad-ar.or.jp
   Google Scholar
• http://www.strokecenter.org/trials
   Google Scholar